SAN DIEGO, March 20, 2017 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces a revised time for its presentation at the 27th Annual Oppenheimer Healthcare Conference. David Moskowitz, Vice President of Strategy and Corporate Communications, is now scheduled to present a corporate overview on Wednesday, March 22, 2017 at 1:00 p.m. Eastern time (10:00 a.m. Pacific time). The conference is being held at The Westin New York Grand Central in New York City.
A live webcast of the corporate presentation will be available on the Company's website at ir.biocept.com. A replay of the presentations will be available for 90 days.
Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company uses its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. The Company's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in circulating tumor DNA (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient's disease and therapeutic options. For additional information, please visit www.biocept.com.
SOURCE Biocept, Inc.